WuXi Biologics (300142.SZ): Clinical research application for respiratory syncytial virus mRNA vaccine accepted

Zhitan Finance and Economics APP News, Watson Bio (300142.SZ) announced that the company, Fudan University, Shanghai Blue Jay Biopharmaceutical Co., Ltd. (hereinafter referred to as "Blue Jay Biopharmaceutical"), and the company's subsidiaries Yuxi Watson Biotechnology Co., Ltd. and Beijing Watson Innovative Biotechnology Co., Ltd. jointly developed a respiratory syncytial virus mRNA vaccine (hereinafter referred to as "this vaccine") has applied for clinical trials to the National Medical Products Administration and recently received the "Acceptance Notice".